Glioblastoma Multiform Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Glioblastoma Multiform clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 84 trials

Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled1 locationNCT07326566
Recruiting
Phase 1Phase 2

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

Breast CancerLung CancersOvarian Cancer+4 more
Filamon LTD80 enrolled3 locationsNCT06926075
Recruiting
Phase 3

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

GlioblastomaNeoplastic DiseaseGlioblastoma (GBM)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited50 enrolled4 locationsNCT07100730
Recruiting
Early Phase 1

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899
Recruiting
Not Applicable

WBSI Guided Personalized Delivery of TTFields

GBMTumor, BrainGlioma Glioblastoma Multiforme
Abramson Cancer Center at Penn Medicine155 enrolled2 locationsNCT05086497
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting
Phase 1Phase 2

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

Glioblastoma Multiforme
Neonc Technologies, Inc.49 enrolled12 locationsNCT02704858
Recruiting
Phase 1

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Glioblastoma MultiformeRecurrent Glioblastoma
Boston Scientific Corporation36 enrolled9 locationsNCT05303467
Recruiting
Not Applicable

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

GlioblastomaGlioblastoma Multiforme
Washington University School of Medicine40 enrolled1 locationNCT05281731
Recruiting
Phase 2

Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients

Glioblastoma Multiforme
AHS Cancer Control Alberta107 enrolled2 locationsNCT04765514
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Phase 2

Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma

Glioblastoma Multiforme, Adult
Centre Paul Strauss75 enrolled3 locationsNCT05653622
Recruiting

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

GlioblastomaGlioblastoma MultiformeGliosarcoma
Baptist Health South Florida120 enrolled1 locationNCT05756985
Recruiting
Phase 1Phase 2

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Lung CancerNon-small Cell Lung CancerSolid Tumor+4 more
Tango Therapeutics, Inc.191 enrolled13 locationsNCT06810544
Recruiting
Phase 1Phase 2

5G-PEARL: Paxalisib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary Gliomas
Institute of Cancer Research, United Kingdom64 enrolled1 locationNCT07391215
Recruiting
Phase 1

GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma

Glioblastoma Multiforme of Brain
Baylor College of Medicine27 enrolled1 locationNCT06815432
Recruiting
Phase 1Phase 2

Study of Pembrolizumab and M032 (NSC 733972)

Glioblastoma MultiformeAnaplastic AstrocytomaGliosarcoma
University of Alabama at Birmingham28 enrolled1 locationNCT05084430
Recruiting
Phase 1

A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma

Glioblastoma (GBM)Newly Diagnosed Glioblastoma Multiforme
CHA University10 enrolled1 locationNCT07143812
Recruiting
Phase 1Phase 2

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom182 enrolled3 locationsNCT06630260